Pharmacological activation of REV-ERBα by SR9009 suppressed aberrant pathological gene expression, prevented cardiomyocyte hypertrophy, reduced fibrosis, and halted progression of advanced heart failure. The gene discussed is NR1D1; the disease is heart failure.